CEFPODOXIME

CEFPODOXIMe
(cef-po-dox'eem)
Vantin
Classifications: antibiotic; third-generation cephalosporin;
Therapeutic: antibiotic
; cephalosporin
Prototype: Cefotaxime sodium
Pregnancy Category: B

Availability

100 mg, 200 mg tablets; 10 mg/mL, 20 mg/mL suspension

Action

Semisynthetic beta-lactam cephalosporin antibiotic. It inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) within the bacterial cell wall.

Therapeutic Effect

Has antibacterial activity resembling that of other third-generation cephalosporins. Stable in the presence of beta-lactamases. Highly active against gram-negative bacteria.

Uses

Gonorrhea, otitis media, lower and upper respiratory tract infections, urinary tract infections.

Unlabeled Uses

Skin and soft tissue infections.

Contraindications

Hypersensitivity to cephalosporins and other beta-lactam antibiotics.

Cautious Use

Renal impairment, history of type I hypersensitivity reactions to penicillins; coagulopathy; history of colitis or other GI disease; lactation, pregnancy (category B).

Route & Dosage

Respiratory Tract, Skin, and Soft Tissue Infections
Adult: PO 200 mg q12h for 10 d
Child: PO 10 mg/kg/d divided q12h

Urinary Tract Infections
Adult: PO 100 mg q12h

Gonorrhea
Adult: PO 200 mg as single dose

Otitis Media
Child (5 mo–12 y): PO 10 mg/kg/d divided q12–24h

Administration

Oral
  • Give with food to enhance absorption.
  • Give 1 h before or 2 h after an antacid.
  • Consult physician regarding patients with renal impairment (i.e., creatinine clearance less than 30 mL/min); dosage intervals should be every 12 h.
  • Patients on hemodialysis should be given usual dose 3 times weekly after hemodialysis.
  • Preparation of suspension: To either the 50 mg/5 mL strength or the 100 mg/5 mL strength, add 25 mL of distilled water, then shake vigorously for 15 seconds. Next, to the 50 mg/5 mL strength add 33 mL, or to the 100 mg/5 mL strength add 32 mL, of distilled water, and shake for at least 3 minutes.
  • Store suspension for up to 14 d in a refrigerator [2°–8° C (36°–46° F)]. Shake well before using.

Adverse Effects (≥1%)

Body as a Whole: Eye itching, cough, epistaxis, fever, decreased appetite, malaise. GI: Diarrhea, nausea, vomiting, abdominal pain, soft stools, flatulance, pseudomembranous colitis (rare). CNS: rare: Headache, asthenia, dizziness, fatigue, anxiety, insomnia, flushing, nightmares, weakness. Urogenital: Vaginal candidiasis. Skin: Urticaria, rash, scaling, peeling.

Interactions

Drug: antacids, ranitidine may decrease absorption. Food: Food may increase the absorption.

Pharmacokinetics

Absorption: 40–50% absorbed from GI tract. Onset: Therapeutic effect in 3 d. Distribution: Distributes well into inflammatory, pulmonary, and pleural fluid, and tonsils. Some distribution into prostate. 40% bound to plasma proteins. Distributed into breast milk. Elimination: 80% in urine. Half-Life: 2–3 h.

Nursing Implications

Assessment & Drug Effects

  • Determine history of hypersensitivity reactions to cephalosporins and penicillins, and history of allergies, particularly to drugs, before therapy is initiated.
  • Lab tests: Perform culture and sensitivity tests before initiation of therapy and periodically during therapy, if indicated. Therapy may be instituted pending test results.
  • Report onset of loose stools or diarrhea. Although pseudomembranous enterocolitis (see Appendix F) rarely occurs, this potentially life-threatening complication should be ruled out as the cause of diarrhea during and after antibiotic therapy.
  • Monitor for manifestations of hypersensitivity (see Appendix F). Discontinue drug and report S&S of hypersensitivity promptly.
  • Monitor I&O rates and pattern: Especially important with high doses; report any significant changes.

Patient & Family Education

  • Report any signs or symptoms of hypersensitivity immediately.
  • Report loose stools, or diarrhea, especially if containing blood, mucus, or pus.
  • Complete the full course of drug therapy even if symptoms improve.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(144)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 06/12/2025 (0.02)
×
Wait 20 seconds...!!!